Synthesis and Characterisation of Platinum(II) Diaminocyclohexane Complexes with Pyridine Derivatives as Anticancer Agents.

Brondwyn S McGhie, Jennette Sakoff, Jayne Gilbert, Christopher P Gordon, Janice R Aldrich-Wright

Open access · goldAbstract read

In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.9field-weighted citation impact, top 19% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

International journal of molecular sciences · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Brondwyn S McGhieNanoscale Organisation and Dynamics Group, School of Science, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia.

Jennette SakoffDepartment of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia.ORCID 0000-0002-7009-5792

Jayne GilbertDepartment of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia.

Christopher P GordonNanoscale Organisation and Dynamics Group, School of Science, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia.ORCID 0000-0001-7583-5609

Janice R Aldrich-WrightNanoscale Organisation and Dynamics Group, School of Science, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia.ORCID 0000-0002-6943-6908

Western Sydney University · AUCalvary Mater Newcastle Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin-type covalent chemotherapeutics are a cornerstone of modern medicinal oncology. However, these drugs remain encumbered with dose-limiting side effects and are susceptible to innate and acquired resistance. The bulk of platinum anticancer research has focused on Cisplatin and its derivatives. Here, we take inspiration from the design of platinum complexes and ligands used successfully with other metals to create six novel complexes. Herein, the synthesis, characterization, DNA binding affinities, and lipophilicity of a series of non-traditional organometallic Pt(II)-complexes are described. These complexes have a basic [Pt(P

Indexed as

Antineoplastic AgentsPlatinumBenzimidazolesCell Line, TumorCisplatinDNAHumansLigandsMCF-7 CellsPyridines2-(2-pyridyl)benzimidazoleAntineoplastic AgentsBenzimidazolesCisplatinDNALigandsPlatinumPyridinesanticancer drugsimidazoleplatinum complexespyridine derivatives

Identifiers

PMID38138979

DOI10.3390/ijms242417150

PMCPMC10742472

OpenAlexW4389337234

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.